TherapeuticsMD, Inc. (Nasdaq: TXMD) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its Listing On Nasdaq
ADVISORY, Oct. 06, 2017 (GLOBE NEWSWIRE) --
TherapeuticsMD, Inc. (Nasdaq:TXMD), an innovative healthcare company focused on developing and commercializing products exclusively for women, will visit the Nasdaq MarketSite in Times Square in celebration of its listing on Nasdaq.
TherapeuticsMD marks the 304th transfer to Nasdaq since 2005, pushing the total market cap of companies that have switched to Nasdaq to more than $1 trillion dollars.
In honor of the occasion, Robert G. Finizio, Co-Founder & Chief Executive Officer, will ring the Opening Bell.
Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Monday, October 9, 2017 – 9:15 a.m. to 9:30 a.m. ET
TherapeuticsMD, Inc. Media Contact:
David DeLucia, CFA
Office – (561) 961-1900 ext. 2010
Mobile – (732) 690-8956
Nasdaq MarketSite Media Contact:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:
For photos from ceremonies and events, please visit our Instagram page:
For livestream of ceremonies and events, please visit our YouTube page:
For news tweets, please visit our Twitter page:
For exciting viral content and ceremony photos, please visit our Tumblr page:
A live stream of the Nasdaq Opening Bell will be available at:
https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx
To obtain a hi-resolution photograph of the Market Open, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market open of your choice.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing products exclusively for women. With its SYMBODA™ technology, TherapeuticsMD is developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The Company’s late stage clinical pipeline includes two phase 3 product candidates: TX-001HR for treatment of moderate-to-severe vasomotor symptoms (VMS) due to menopause and TX-004HR for treatment of moderate-to-severe vaginal pain during sexual intercourse (dyspareunia), a symptom of vulvar and vaginal atrophy (VVA) due to menopause. The Company also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaMedMD® and BocaGreenMD® brands.
Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately $12 trillion. To learn more, visit: http://business.nasdaq.com